Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Taiwan: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "Taiwan: These 39 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can AXUMIN (fluciclovine f-18) generic drug versions launch in Taiwan?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Taiwan Patent 200,800,869
Patent Title: Precursor compound of radioactive halogen labeled organic compound

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can AXUMIN (fluciclovine f-18) generic drug versions launch in Taiwan?

Generic name: fluciclovine f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 28, 2026
Generic Entry Controlled by: Taiwan Patent I371439

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. Additional details are available on the fluciclovine f-18 profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Taiwan?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 05, 2026
Generic Entry Controlled by: Taiwan Patent 200,838,527
Patent Title: Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Taiwan?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Taiwan Patent 200,831,486
Patent Title: Compounds and compositions as protein kinase inhibitors

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Taiwan?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Taiwan Patent I410416

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Taiwan?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Taiwan Patent I413641

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can NESINA (alogliptin benzoate) generic drug versions launch in Taiwan?

Generic name: alogliptin benzoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Taiwan Patent 200,836,774
Patent Title: Solid preparation

Drug Price Trends for NESINA
NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. Additional details are available on the alogliptin benzoate profile page.

When can OSENI (alogliptin benzoate; pioglitazone hydrochloride) generic drug versions launch in Taiwan?

Generic name: alogliptin benzoate; pioglitazone hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 01, 2027
Generic Entry Controlled by: Taiwan Patent 200,836,775

Drug Price Trends for OSENI
OSENI is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug. There has been litigation on patents covering OSENI

See drug price trends for OSENI.

The generic ingredient in OSENI is alogliptin benzoate; pioglitazone hydrochloride. Additional details are available on the alogliptin benzoate; pioglitazone hydrochloride profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent 200,843,795
Patent Title: Stable digestive enzyme compositions

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent 201,422,233
Patent Title: Stable digestive enzyme compositions

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent I421090

PANCREAZE is a drug marketed by

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent 200,843,795
Patent Title: Stable digestive enzyme compositions

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent 201,422,233
Patent Title: Stable digestive enzyme compositions

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch in Taiwan?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Taiwan Patent I421090

ZENPEP is a drug marketed by

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Taiwan?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2027
Generic Entry Controlled by: Taiwan Patent I350185

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Taiwan?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Taiwan Patent 200,902,089
Patent Title: Solid pharmaceutical composition

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can EDARBI (azilsartan kamedoxomil) generic drug versions launch in Taiwan?

Generic name: azilsartan kamedoxomil
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 28, 2027
Generic Entry Controlled by: Taiwan Patent I415634

Drug Price Trends for EDARBI
EDARBI is a drug marketed by Azurity. There is one patent protecting this drug. There has been litigation on patents covering EDARBI

See drug price trends for EDARBI.

The generic ingredient in EDARBI is azilsartan kamedoxomil. Additional details are available on the azilsartan kamedoxomil profile page.

When can VARUBI (rolapitant hydrochloride) generic drug versions launch in Taiwan?

Generic name: rolapitant hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 04, 2027
Generic Entry Controlled by: Taiwan Patent 200,815,439
Patent Title: Hydrochloride salts of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and preparation process therefor

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

The generic ingredient in VARUBI is rolapitant hydrochloride. Additional details are available on the rolapitant hydrochloride profile page.

When can INLYTA (axitinib) generic drug versions launch in Taiwan?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Taiwan Patent 200,911,781

INLYTA is a drug marketed by Pf Prism Cv. There are four patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. Additional details are available on the axitinib profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Taiwan?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Taiwan Patent 201,410,240
Patent Title: Pharmaceutical tablets, solid oral pharmaceutical dosage forms, pharmaceutical capsules and pharmaceutical granules comprising 3'-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carbox

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Taiwan?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Taiwan Patent I439267

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Taiwan?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Taiwan Patent I538674

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can TRADJENTA (linagliptin) generic drug versions launch in Taiwan?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 03, 2027
Generic Entry Controlled by: Taiwan Patent 200,812,648
Patent Title: DPP IV inhibitor formulations

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. Additional details are available on the linagliptin profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Taiwan?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Taiwan Patent 201,002,323
Patent Title: Novel piperazine salts as D3/D2 antagonists

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can VRAYLAR (cariprazine hydrochloride) generic drug versions launch in Taiwan?

Generic name: cariprazine hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 11, 2027
Generic Entry Controlled by: Taiwan Patent I424846

Drug Price Trends for VRAYLAR
VRAYLAR is a drug marketed by Abbvie. There are five patents protecting this drug. There has been litigation on patents covering VRAYLAR

See drug price trends for VRAYLAR.

The generic ingredient in VRAYLAR is cariprazine hydrochloride. Additional details are available on the cariprazine hydrochloride profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Taiwan?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Taiwan Patent 200,906,437
Patent Title: Pasireotide formulation

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in Taiwan?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: Taiwan Patent I412373

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can XADAGO (safinamide mesylate) generic drug versions launch in Taiwan?

Generic name: safinamide mesylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 15, 2027
Generic Entry Controlled by: Taiwan Patent I393700

Drug Price Trends for XADAGO
XADAGO is a drug marketed by Mdd Us. There are three patents protecting this drug. There has been litigation on patents covering XADAGO

See drug price trends for XADAGO.

The generic ingredient in XADAGO is safinamide mesylate. Additional details are available on the safinamide mesylate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Taiwan?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Taiwan Patent 200,918,550
Patent Title: Synthetic bile acid composition, method, and preparation

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Taiwan?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Taiwan Patent 201,534,684
Patent Title: Synthetic bile acid composition, method, and preparation

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in Taiwan?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: Taiwan Patent I503327

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide) generic drug versions launch in Taiwan?

Generic name: aliskiren hemifumarate; hydrochlorothiazide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 22, 2027
Generic Entry Controlled by: Taiwan Patent 200,808,358

Drug Price Trends for TEKTURNA HCT
TEKTURNA HCT is a drug marketed by Noden Pharma. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering TEKTURNA HCT

See drug price trends for TEKTURNA HCT.

The generic ingredient in TEKTURNA HCT is aliskiren hemifumarate; hydrochlorothiazide. Additional details are available on the aliskiren hemifumarate; hydrochlorothiazide profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Taiwan?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,406,743
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch in Taiwan?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,546,054
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Taiwan?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,406,743
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Taiwan?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,546,054
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch in Taiwan?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent I421245

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Fifteen tentatively approved generics are ready to enter the market. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Taiwan?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,406,743
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Taiwan?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent 201,546,054
Patent Title: Crystal structures of SGLT2 inhibitors and processes for preparing same

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch in Taiwan?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2027
Generic Entry Controlled by: Taiwan Patent I421245

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Taiwan?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Taiwan Patent 200,906,409
Patent Title: Pyridazinone derivatives

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can TEPMETKO (tepotinib hydrochloride) generic drug versions launch in Taiwan?

Generic name: tepotinib hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 12, 2027
Generic Entry Controlled by: Taiwan Patent I501768

TEPMETKO is a drug marketed by Emd Serono Inc. There are eight patents protecting this drug. There has been litigation on patents covering TEPMETKO

See drug price trends for TEPMETKO.

The generic ingredient in TEPMETKO is tepotinib hydrochloride. Additional details are available on the tepotinib hydrochloride profile page.

When can KAZANO (alogliptin benzoate; metformin hydrochloride) generic drug versions launch in Taiwan?

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 19, 2027
Generic Entry Controlled by: Taiwan Patent I421102

Drug Price Trends for KAZANO
KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

When can RELISTOR (methylnaltrexone bromide) generic drug versions launch in Taiwan?

Generic name: methylnaltrexone bromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: July 30, 2027
Generic Entry Controlled by: Taiwan Patent I489984

Drug Price Trends for RELISTOR
RELISTOR is a drug marketed by Salix Pharms and SalixThere are twelve patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering RELISTOR

See drug price trends for RELISTOR.

The generic ingredient in RELISTOR is methylnaltrexone bromide. Additional details are available on the methylnaltrexone bromide profile page.

When can PROMACTA (eltrombopag olamine) generic drug versions launch in Taiwan?

Generic name: eltrombopag olamine
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 01, 2027
Generic Entry Controlled by: Taiwan Patent 200,843,742
Patent Title: Novel pharmaceutical composition

PROMACTA is a drug marketed by Novartis. There is one patent protecting this drug and two Paragraph IV challenges. There has been litigation on patents covering PROMACTA

See drug price trends for PROMACTA.

The generic ingredient in PROMACTA is eltrombopag olamine. Additional details are available on the eltrombopag olamine profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Taiwan?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Taiwan Patent 200,817,412
Patent Title: Pharmaceutical compositions 457

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can BRILINTA (ticagrelor) generic drug versions launch in Taiwan?

Generic name: ticagrelor
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Taiwan Patent I482772

Drug Price Trends for BRILINTA
BRILINTA is a drug marketed by Astrazeneca. There are two patents protecting this drug and two Paragraph IV challenges. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering BRILINTA

See drug price trends for BRILINTA.

The generic ingredient in BRILINTA is ticagrelor. Additional details are available on the ticagrelor profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Taiwan?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Taiwan Patent 200,927,136
Patent Title: Pharmaceutical compositions

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can INTRAROSA (prasterone) generic drug versions launch in Taiwan?

Generic name: prasterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 10, 2027
Generic Entry Controlled by: Taiwan Patent I609688

Drug Price Trends for INTRAROSA
INTRAROSA is a drug marketed by Millicent. There are three patents protecting this drug. There has been litigation on patents covering INTRAROSA

See drug price trends for INTRAROSA.

The generic ingredient in INTRAROSA is prasterone. Additional details are available on the prasterone profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Taiwan?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Taiwan Patent 200,924,759
Patent Title: Process for the manufacture of a pharmaceutical product

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PREPOPIK (citric acid; magnesium oxide; sodium picosulfate) generic drug versions launch in Taiwan?

Generic name: citric acid; magnesium oxide; sodium picosulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 12, 2027
Generic Entry Controlled by: Taiwan Patent I418352

PREPOPIK is a drug marketed by Ferring Pharms Inc. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market. There has been litigation on patents covering PREPOPIK

See drug price trends for PREPOPIK.

The generic ingredient in PREPOPIK is citric acid; magnesium oxide; sodium picosulfate. Additional details are available on the citric acid; magnesium oxide; sodium picosulfate profile page.

When can PYLARIFY (piflufolastat f-18) generic drug versions launch in Taiwan?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Taiwan Patent I492761

PYLARIFY is a drug marketed by Progenics Pharms Inc and AphelionThere are six patents protecting this drug.

See drug price trends for PYLARIFY.

The generic ingredient in PYLARIFY is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can PYLARIFY TRUVU (piflufolastat f-18) generic drug versions launch in Taiwan?

Generic name: piflufolastat f-18
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2027
Generic Entry Controlled by: Taiwan Patent I492761

PYLARIFY TRUVU is a drug marketed by Aphelion. There are six patents protecting this drug.

The generic ingredient in PYLARIFY TRUVU is piflufolastat f-18. Additional details are available on the piflufolastat f-18 profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Taiwan?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Taiwan Patent 200,938,210
Patent Title: Pharmaceutical compositions

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Taiwan?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Taiwan Patent 201,509,423
Patent Title: Pharmaceutical compositions

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Taiwan?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Taiwan Patent I468167

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can VELPHORO (sucroferric oxyhydroxide) generic drug versions launch in Taiwan?

Generic name: sucroferric oxyhydroxide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 16, 2027
Generic Entry Controlled by: Taiwan Patent I592159

Drug Price Trends for VELPHORO
VELPHORO is a drug marketed by Vifor Fresenius. There are eleven patents protecting this drug. There has been litigation on patents covering VELPHORO

See drug price trends for VELPHORO.

The generic ingredient in VELPHORO is sucroferric oxyhydroxide. Additional details are available on the sucroferric oxyhydroxide profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Taiwan?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Taiwan Patent 200,927,146
Patent Title: Antibacterial aminoglycoside analogs

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can ZEMDRI (plazomicin sulfate) generic drug versions launch in Taiwan?

Generic name: plazomicin sulfate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 21, 2027
Generic Entry Controlled by: Taiwan Patent I425947

ZEMDRI is a drug marketed by Cipla Usa. There are four patents protecting this drug. There has been litigation on patents covering ZEMDRI

See drug price trends for ZEMDRI.

The generic ingredient in ZEMDRI is plazomicin sulfate. Additional details are available on the plazomicin sulfate profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Taiwan?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 200,927,733
Patent Title: Novel compounds and compositions and methods of use

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Taiwan?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 201,018,463
Patent Title: Compounds, compositions and methods of using same for modulating uric acid levels

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Taiwan?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 201,022,216
Patent Title: Compounds, compositions and methods of using same for modulating uric acid levels

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can DUZALLO (allopurinol; lesinurad) generic drug versions launch in Taiwan?

Generic name: allopurinol; lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent I377200

Drug Price Trends for DUZALLO
DUZALLO is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering DUZALLO

See drug price trends for DUZALLO.

The generic ingredient in DUZALLO is allopurinol; lesinurad. Additional details are available on the allopurinol; lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Taiwan?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 200,927,733
Patent Title: Novel compounds and compositions and methods of use

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Taiwan?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 201,018,463
Patent Title: Compounds, compositions and methods of using same for modulating uric acid levels

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Taiwan?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent 201,022,216
Patent Title: Compounds, compositions and methods of using same for modulating uric acid levels

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ZURAMPIC (lesinurad) generic drug versions launch in Taiwan?

Generic name: lesinurad
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: November 27, 2027
Generic Entry Controlled by: Taiwan Patent I377200

ZURAMPIC is a drug marketed by Ironwood Pharms Inc. There are eight patents protecting this drug. There has been litigation on patents covering ZURAMPIC

See drug price trends for ZURAMPIC.

The generic ingredient in ZURAMPIC is lesinurad. Additional details are available on the lesinurad profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Taiwan?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Taiwan Patent 200,840,582
Patent Title: Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can ALIQOPA (copanlisib dihydrochloride) generic drug versions launch in Taiwan?

Generic name: copanlisib dihydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Taiwan Patent I406662

ALIQOPA is a drug marketed by Bayer Healthcare. There are three patents protecting this drug.

See drug price trends for ALIQOPA.

The generic ingredient in ALIQOPA is copanlisib dihydrochloride. Additional details are available on the copanlisib dihydrochloride profile page.

When can SIRTURO (bedaquiline fumarate) generic drug versions launch in Taiwan?

Generic name: bedaquiline fumarate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 04, 2027
Generic Entry Controlled by: Taiwan Patent I417098

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. Additional details are available on the bedaquiline fumarate profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in Taiwan?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 07, 2027
Generic Entry Controlled by: Taiwan Patent 201,124,402
Patent Title: Compounds and compositions as protein kinase inhibitors

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Taiwan?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 10, 2027
Generic Entry Controlled by: Taiwan Patent 200,831,102
Patent Title: 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

When can XERMELO (telotristat etiprate) generic drug versions launch in Taiwan?

Generic name: telotristat etiprate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 10, 2027
Generic Entry Controlled by: Taiwan Patent I412365

XERMELO is a drug marketed by Tersera. There are five patents protecting this drug.

See drug price trends for XERMELO.

The generic ingredient in XERMELO is telotristat etiprate. Additional details are available on the telotristat etiprate profile page.

Taiwan Branded and Generic Drug Markets: Regulatory Opportunities, Patent Risks, and Commercial Outlook

Last updated: October 11, 2026

Taiwan is a regulated, reimbursement-driven pharmaceutical market with near-universal National Health Insurance coverage, strong domestic generic manufacturing, and increasing regulatory alignment with international standards. Branded products retain value through patented therapies, hospital relationships, clinical evidence, and reimbursement positioning. Generics compete primarily on price, supply reliability, bioequivalence, manufacturing quality, and National Health Insurance access.

The main commercial opportunity is in high-value specialty drugs, oncology, rare disease therapies, biosimilars, complex generics, and products with differentiated delivery systems. The principal risks are Taiwan’s price-controlled reimbursement system, mandatory price adjustments, market concentration among domestic manufacturers, patent-linkage litigation, data-exclusivity limits, and the difficulty of achieving premium pricing without local clinical or economic evidence.

What is the size and structure of Taiwan’s pharmaceutical market?

Taiwan’s pharmaceutical market is dominated by the National Health Insurance system. More than 99% of residents are covered by NHI, making reimbursement status more important than private-pay demand for most prescription medicines (National Health Insurance Administration [NHIA], 2024).

Taiwan does not publish a single market-size measure that captures all hospital, retail, self-pay, traditional medicine, and pharmaceutical distribution activity. Public NHI data indicate annual reimbursed drug expenditure in the high hundreds of billions of New Taiwan dollars, depending on the accounting year and whether certain hospital and specialty categories are included. Commercial market estimates commonly place the total prescription pharmaceutical market in the several-billion-U.S.-dollar range.

Market characteristic Taiwan position
Population Approximately 23 million
Health coverage Near-universal NHI coverage
Primary payer Taiwan National Health Insurance Administration
Regulatory authority Taiwan Food and Drug Administration, TFDA
Reimbursement authority NHIA
Main purchasing channels Hospitals, clinics, pharmacies, public tenders
Domestic industry Strong generic, API, CDMO, and contract manufacturing base
Market access determinant TFDA approval plus NHI listing and reimbursement price
Main commercial constraint Price erosion and reimbursement controls

Taiwan’s hospital sector has substantial purchasing power. Medical centers and regional hospitals influence prescribing, formulary inclusion, tender awards, and adoption of higher-priced branded products. Clinics and community pharmacies remain important for chronic disease products, but the economic value of a product depends heavily on the reimbursed price and dispensing channel.

How does Taiwan’s branded drug market operate?

Branded drugs compete through patent protection, regulatory exclusivity, clinical differentiation, physician familiarity, supply continuity, and reimbursement positioning.

Innovator products generally enter Taiwan through one of three routes:

  1. A full new-drug application supported by preclinical and clinical data.
  2. A bridging or reliance-based strategy using foreign clinical data supplemented by Taiwan-specific evidence where required.
  3. A local registration pathway for products already approved in other jurisdictions, subject to TFDA requirements.

A multinational company usually needs a Taiwan marketing authorization holder, local representative, or affiliate. Commercial success depends on more than approval. NHI listing, price negotiation, hospital formulary review, and post-marketing obligations determine practical market access.

Which branded drug categories have the strongest opportunities?

The strongest opportunities are concentrated in products with high unmet need or limited substitution:

Category Commercial opportunity Main barrier
Oncology High clinical demand and specialty pricing NHI budget controls and comparative evidence
Rare disease Potential reimbursement priority and orphan incentives Small populations and evidence requirements
Immunology Growing biologic use Biosimilar competition and price negotiations
Diabetes and obesity Large patient populations Reimbursement restrictions and tender pressure
Cardiovascular disease Large volume opportunity Severe generic competition
Anti-infectives Institutional demand Price erosion and procurement competition
Advanced injectables Less direct substitution Manufacturing and quality requirements
Cell and gene therapies Regulatory first-mover opportunity High evidence, logistics, and reimbursement hurdles

TFDA has developed pathways for priority review, orphan drugs, pediatric medicines, and products addressing significant public health needs. These mechanisms can reduce review time or improve regulatory sequencing, but they do not automatically produce premium NHI reimbursement.

What is the Taiwan generic drug market?

Taiwan has a mature generic industry with domestic manufacturers supplying oral solids, injectables, topical products, active pharmaceutical ingredients, and contract development and manufacturing services.

The generic market is divided into:

  • Branded generics marketed under local company names.
  • Authorized generics associated with originator companies.
  • Unbranded or lower-priced generic products.
  • Complex generics requiring device, formulation, or clinical equivalence evidence.
  • Biosimilars, which are regulated separately from conventional chemical generics.

Local companies often compete through hospital relationships, broad product portfolios, reliable supply, and regulatory execution. Taiwan’s generic sector includes manufacturers with domestic sales models and companies focused on exports to regulated markets such as the United States, Europe, Japan, and Southeast Asia.

How do generics obtain approval in Taiwan?

Generic applicants generally rely on an abbreviated application supported by pharmaceutical quality data and evidence of therapeutic equivalence, commonly including bioequivalence studies. The applicant must demonstrate compliance with TFDA requirements for:

  • Active ingredient identity and quality.
  • Manufacturing controls.
  • Stability.
  • Dissolution and performance.
  • Bioequivalence where required.
  • Good manufacturing practice.
  • Labeling and risk-management obligations.

TFDA applies current GMP expectations and has increased scrutiny of data integrity, overseas manufacturing sites, sterile production, nitrosamine controls, and supply-chain quality.

The product must then obtain NHI reimbursement or secure a commercially viable self-pay channel. TFDA approval without NHI listing can leave a generic with limited market access, particularly when physicians and hospitals favor reimbursed alternatives.

What patents protect branded drugs in Taiwan?

Taiwan grants patents with a standard term of 20 years from the filing date, subject to statutory requirements. Pharmaceutical patent-term adjustment or extension can be available for regulatory delays, generally within a maximum extension framework under Taiwan’s Patent Act (Taiwan Intellectual Property Office [TIPO], 2024).

Patent coverage may include:

  • Composition-of-matter claims.
  • Salts, polymorphs, crystalline forms, and solvates.
  • Pharmaceutical compositions.
  • Dosage regimens.
  • Patient populations.
  • Combination therapies.
  • Formulation and release profiles.
  • Manufacturing processes.
  • Medical-use claims.

Patent strength depends on claim scope, remaining term, validity against prior art, enablement, written description, and the ability to obtain an injunction or damages remedy. A formulation or method-of-use patent can delay generic substitution even after the core compound patent expires, but its practical value depends on how narrowly the generic can design around the claims.

When does a branded drug lose exclusivity in Taiwan?

Exclusivity ends through a combination of events rather than a single date:

Protection Typical duration or trigger
Core patent Up to 20 years from filing, subject to adjustments
Pharmaceutical patent extension Available for qualifying regulatory delay, subject to statutory limits
New-drug data exclusivity Generally five years under Taiwan’s Drug Act framework
New indication protection May receive a separate period of protection in qualifying circumstances
Orphan-drug incentives Additional regulatory and market protections may apply
Patent-linkage stay Can delay approval or marketing after a qualifying patent challenge
Regulatory exclusivity Ends when the statutory period expires or a lawful reliance pathway opens

A generic may face several overlapping barriers. The compound patent may expire first, while formulation, use, or manufacturing patents remain in force. The generic applicant must assess each patent and regulatory protection separately.

What is Taiwan’s patent-linkage system?

Taiwan introduced a patent-linkage system for pharmaceuticals under amendments to the Pharmaceutical Affairs Act. The system requires innovators to list eligible patents associated with new drugs and requires generic applicants to make patent-related certifications or declarations.

The framework broadly resembles the U.S. Hatch-Waxman model but operates within Taiwan’s own statutory and administrative structure.

Patent-linkage element Taiwan approach
Patent listing Innovator submits eligible patent information within the statutory period
Generic certification Applicant identifies whether listed patents are not infringed, invalid, expired, or not applicable
Patent challenge A challenge can trigger notification and litigation rights
Litigation window Innovator may sue within the statutory period after notification
Approval delay A qualifying dispute can create a temporary regulatory stay
First generic incentive Taiwan provides a limited exclusivity incentive for qualifying first challengers

Patent-linkage strategy is central to generic launch planning. A Paragraph IV-style challenge can create first-mover value, but it also exposes the applicant to patent litigation, launch-at-risk damages, manufacturing costs, and potential injunctions.

Which companies are challenging branded drug patents in Taiwan?

Taiwan’s patent challengers are generally domestic generic companies, regional pharmaceutical groups, and multinational generic manufacturers. Publicly available litigation data do not provide a single continuously updated market ranking of challengers across all products.

Typical challengers include:

  • Taiwanese generic manufacturers with hospital sales networks.
  • API and finished-dose manufacturers seeking vertical integration.
  • Regional companies targeting high-value products.
  • Global generic companies entering through local partners.
  • Companies pursuing first-generic or complex-generic opportunities.

The commercial value of a challenge is highest when the product has substantial NHI expenditure, limited therapeutic substitutes, and a patent estate vulnerable to invalidity or design-around arguments.

What is the Orange Book status of drugs in Taiwan?

Taiwan does not use the U.S. FDA Orange Book as its governing patent-listing database. Taiwan operates its own patent-linkage system and administrative processes through TFDA and related government agencies.

For diligence purposes, companies should review:

  • TFDA drug approval and product databases.
  • Taiwan patent records maintained by TIPO.
  • Patent-linkage listings for relevant new drugs.
  • Court decisions and Taiwan Intellectual Property and Commercial Court filings.
  • NHI reimbursement and price records.
  • TFDA safety communications and regulatory announcements.

A U.S. Orange Book listing does not automatically establish enforceable patent rights in Taiwan. The Taiwan patent must be separately filed, granted, maintained, and linked to the relevant approved drug where required.

What formulation patents protect drugs in Taiwan?

Formulation patents are commercially important after compound-patent expiry. Common protected technologies include:

  • Extended-release tablets and capsules.
  • Enteric-coated products.
  • Abuse-deterrent formulations.
  • Long-acting injectables.
  • Liposomal delivery systems.
  • Nanoparticle formulations.
  • Fixed-dose combinations.
  • Pediatric liquid formulations.
  • Transdermal systems.
  • Device-linked inhalation products.

Formulation patents are strongest when they cover a technically defined product with measurable performance characteristics. Broad functional claims can face validity risk if prior art demonstrates the same result or if the specification does not support the claimed scope.

A generic company may avoid infringement by changing excipients, release mechanisms, particle size, manufacturing steps, dosage strength, or delivery device. Such changes can create new bioequivalence, stability, or clinical requirements.

What is the biosimilar risk in Taiwan?

Biosimilar competition is increasing but remains more complex than conventional generic substitution. Biosimilar applicants must demonstrate analytical similarity, quality comparability, and an appropriate clinical development package under TFDA requirements and applicable international standards.

The principal biosimilar opportunities are in:

  • Insulin.
  • Human growth hormone.
  • Erythropoietin.
  • Monoclonal antibodies.
  • Granulocyte colony-stimulating factors.
  • Fertility products.
  • Infliximab, adalimumab, trastuzumab, and related biologics where patent and reimbursement conditions permit.

Biosimilar uptake depends on physician confidence, hospital procurement, interchangeability policy, reimbursement differentials, and originator contracting. Taiwan’s market is more favorable to biosimilars when NHI reimbursement creates a clear price advantage or when hospitals use tenders to reduce biologic expenditure.

How does Taiwan regulate drug pricing and reimbursement?

TFDA regulates safety, efficacy, quality, and market authorization. NHIA determines NHI reimbursement, listing, and price.

A company must distinguish between:

  • Regulatory approval.
  • NHI reimbursement.
  • Hospital formulary adoption.
  • Actual prescribing and dispensing.
  • Self-pay commercialization.

Taiwan uses price controls and periodic price adjustments. NHI reimbursement prices can decline when market prices, procurement behavior, or generic competition change. This creates a significant gap between regulatory exclusivity and economic exclusivity.

What are the main reimbursement challenges?

The main challenges are:

  1. Lower launch prices than in many Western markets.
  2. Reimbursement negotiations based on budget impact.
  3. Periodic price reductions.
  4. Reference pricing and therapeutic-category comparisons.
  5. Hospital tender pressure.
  6. Limited ability to sustain premium prices without differentiated outcomes.
  7. Restrictions on prescribing outside approved reimbursement criteria.

High-cost drugs may require health technology assessment, pharmacoeconomic evidence, risk-sharing arrangements, price-volume agreements, or restricted reimbursement criteria. Taiwan has expanded its use of evidence-based reimbursement analysis, particularly for oncology, rare disease, and specialty therapies.

What regulatory opportunities exist for foreign pharmaceutical companies?

Foreign companies can use Taiwan as both a commercial market and a regional regulatory and manufacturing base.

Market-entry opportunities

  • Launching oncology and rare disease therapies through priority pathways.
  • Licensing Taiwan-approved products to domestic manufacturers.
  • Using local partners for NHI and hospital access.
  • Establishing local packaging, quality, or distribution capacity.
  • Introducing complex generics before broad commodity competition develops.
  • Developing biosimilar partnerships with domestic companies.
  • Exporting Taiwan-manufactured products to other regulated markets.

Taiwan’s domestic pharmaceutical companies are potential partners for licensing, co-development, contract manufacturing, and distribution. Partnership value is highest where the local company has TFDA experience, hospital access, NHI expertise, and manufacturing capacity for regulated exports.

Regulatory reliance and international alignment

Taiwan has pursued greater alignment with the International Council for Harmonisation and international GMP standards. Foreign clinical data may be usable, but TFDA may require bridging evidence, local pharmacokinetic data, ethnic sensitivity analysis, or Taiwan-specific quality documentation depending on the product and application.

A global development program should treat Taiwan as a separate regulatory market while designing the dossier for maximum cross-jurisdiction reuse.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers include:

  • TFDA GMP inspection requirements.
  • Sterile manufacturing validation.
  • Data-integrity controls.
  • Supply-chain qualification.
  • Nitrosamine and elemental-impurity controls.
  • Serialization and traceability requirements.
  • Local-language labeling and documentation.
  • Import licensing and quality-release obligations.

IP barriers include:

  • Taiwan-specific patent prosecution.
  • Patent-term calculations.
  • Patent linkage.
  • Formulation and use patents.
  • Process patents that affect API sourcing.
  • Trade secrets covering manufacturing processes.
  • Regulatory data protection.
  • Freedom-to-operate analysis for imported APIs and finished products.

Taiwan’s patent system is territorial. A U.S., European, Japanese, or Chinese patent does not create direct infringement liability in Taiwan unless a corresponding Taiwan patent exists.

How does Taiwan compare with South Korea and Japan?

Issue Taiwan South Korea Japan
Main payer NHI National Health Insurance National Health Insurance
Generic penetration High and expanding High High but brand loyalty remains relevant
Price pressure Strong Strong Strong
Patent linkage Yes Yes More limited and structurally different
Market scale Smaller Larger Much larger
Local manufacturing Strong Strong Strong
Premium opportunity Specialty and rare disease Specialty and biologics Specialty, oncology, advanced therapies
Primary access barrier Reimbursement price Reimbursement and local evidence Pricing revisions and clinical evidence

Taiwan offers a smaller but more concentrated market than Japan or South Korea. Its scale limits revenue from commodity products but can reduce commercial complexity for companies with strong hospital, reimbursement, and local-partner capabilities.

What generic launch scenarios are most likely?

Scenario 1: Immediate post-expiry entry

Several generic companies enter after core patent expiry. Prices decline rapidly, and hospital tenders determine market share. This is most likely for high-volume oral solid products.

Scenario 2: First-challenger launch

A generic company challenges a listed patent, wins or settles, and obtains a first-generic advantage. The opportunity can be attractive, but litigation cost and launch-at-risk exposure are high.

Scenario 3: Formulation-specific delay

The compound patent expires, but a formulation or method-of-use patent remains. Generic entrants either design around the patent or launch a narrower indication or dosage form.

Scenario 4: Authorized or licensed generic

The originator collaborates with a domestic company to launch a lower-priced product while protecting part of the branded franchise.

Scenario 5: Biosimilar tender displacement

A biosimilar enters through hospital tenders and gains share without immediate broad physician substitution. Price competition is strongest in institutional channels.

How strong is the patent estate for Taiwan drug products?

Patent strength should be assessed using a weighted framework:

Factor Strong position Weak position
Core patent life More than five years remaining Near expiry
Claim type Composition or robust formulation Narrow process or use claim
Prior art Limited vulnerability Crowded technical field
Regulatory linkage Listed and timely Not listed or procedurally defective
Product differentiation Difficult to replicate Easy to design around
Litigation record Validated in comparable courts Repeated invalidity findings
Manufacturing barrier Complex and confidential Commodity production
Reimbursement High value and limited substitutes Low-price competitive category

A branded company with only a short remaining patent term and a narrow formulation patent has limited ability to prevent generic erosion. A company with composition, formulation, device, manufacturing, and use patents has a stronger but more expensive enforcement position.

What litigation and settlement issues affect Taiwan launches?

Taiwan patent litigation can affect both regulatory approval and commercial launch. The most important issues are:

  • Timely notification of patent certifications.
  • Validity and infringement of listed patents.
  • Availability of preliminary or permanent injunctions.
  • Damages from launch-at-risk sales.
  • Competition-law limits on settlement terms.
  • Licensing restrictions.
  • Supply and distribution commitments.
  • Whether a settlement preserves earlier generic entry.

Settlement agreements may include delayed-entry dates, licenses, authorized-generic arrangements, manufacturing rights, or geographic limitations. Companies must assess whether the settlement could attract scrutiny under Taiwan’s Fair Trade Act, particularly where it delays competition without a clear procompetitive basis.

What revenue exposure exists for originators and generic entrants?

Originator exposure is highest when a product has:

  • Large NHI reimbursement expenditure.
  • A high gross margin.
  • Few therapeutic substitutes.
  • A patent expiry within three years.
  • A formulation or use patent vulnerable to challenge.
  • Significant hospital dependence.
  • No authorized-generic strategy.

Generic revenue potential is highest when the applicant has:

  • First-challenger status.
  • Reliable API supply.
  • TFDA-ready documentation.
  • Hospital tender access.
  • Manufacturing scale.
  • A product with limited current competition.
  • A price strategy that preserves margin after NHI reductions.

Taiwan revenue should be modeled as a net reimbursed price multiplied by realistic market share, not as a percentage of global list price. Scenarios should include immediate multi-source entry, one-year delayed entry, authorized-generic competition, and biosimilar tender substitution.

Key Takeaways

  • Taiwan is a concentrated, NHI-driven pharmaceutical market with strong domestic generic manufacturing.
  • TFDA approval does not guarantee commercial success; NHI reimbursement and hospital access determine revenue.
  • Branded products retain value in oncology, rare disease, biologics, advanced formulations, and therapies with strong clinical differentiation.
  • Generic competition is intense in conventional oral solids and chronic-care medicines.
  • Taiwan’s patent-linkage system creates meaningful opportunities for first generic applicants but increases litigation exposure.
  • Taiwan has no U.S.-style Orange Book; local patent and TFDA records must be reviewed independently.
  • Formulation, dosage-regimen, manufacturing, and method-of-use patents can extend practical exclusivity after compound expiry.
  • Biosimilar adoption is likely to expand through hospital procurement and reimbursement price competition.
  • The strongest foreign-company strategy combines TFDA regulatory planning, NHI access, a domestic commercial partner, and Taiwan-specific freedom-to-operate analysis.
  • Revenue forecasts should incorporate mandatory price erosion, tender discounts, reimbursement restrictions, and rapid generic entry.

FAQs

Does Taiwan recognize U.S. FDA approval for drug registration?

No. U.S. FDA approval can support the regulatory dossier, but Taiwan requires a TFDA application and Taiwan-specific compliance with its pharmaceutical, quality, labeling, and manufacturing requirements.

Is Taiwan a favorable market for first generic applicants?

It can be. A first generic applicant may obtain a limited exclusivity advantage under Taiwan’s patent-linkage framework, but the opportunity depends on patent validity, litigation timing, NHI price, and the number of competing applicants.

Can a foreign pharmaceutical company obtain NHI reimbursement without a Taiwan subsidiary?

A foreign company generally needs an approved local regulatory and commercial structure, such as a Taiwan marketing authorization holder, affiliate, or qualified local partner. Practical reimbursement access also requires local pricing and hospital-market capabilities.

Are biosimilars automatically interchangeable with originator biologics in Taiwan?

No. Biosimilar approval, substitution, and interchangeability are separate regulatory and clinical-policy questions. Hospital formularies, physicians, reimbursement rules, and procurement policies determine actual switching behavior.

How long does regulatory data exclusivity last for new drugs in Taiwan?

Taiwan generally provides five years of data exclusivity for qualifying new drugs, subject to the Drug Act and implementing rules. Separate protections may apply to qualifying new indications, orphan drugs, or other specially regulated products.

References

  1. National Health Insurance Administration. (2024). National Health Insurance annual report and pharmaceutical reimbursement information. Ministry of Health and Welfare, Taiwan. https://www.nhi.gov.tw/

  2. Taiwan Food and Drug Administration. (2024). Drug regulatory information and pharmaceutical application requirements. Ministry of Health and Welfare, Taiwan. https://www.fda.gov.tw/

  3. Taiwan Intellectual Property Office. (2024). Taiwan Patent Act and pharmaceutical patent-term extension information. Ministry of Economic Affairs, Taiwan. https://www.tipo.gov.tw/

  4. Ministry of Health and Welfare. (2024). Pharmaceutical Affairs Act and related regulations. Taiwan. https://law.moj.gov.tw/

  5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2024). ICH guidelines and regulatory cooperation materials. https://www.ich.org/

  6. Taiwan Food and Drug Administration. (2024). Patent linkage system for pharmaceutical products. Ministry of Health and Welfare, Taiwan. https://www.fda.gov.tw/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.